A federal judge has certified a class of direct purchasers of the drug Provigil in their antitrust case against generic drug makers Ranbaxy Laboratories and Mylan Pharmaceuticals.
U.S. District Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania granted class status to direct purchaser plaintiffs who claimed the drug companies delayed the introduction of a generic version of the wakefulness drug Provigil into the market.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
